At a pivotal moment for cannabis culture and business, Colombia makes a bold move toward modernizing therapeutic access: medicinal cannabis flower will now be sold domestically in pharmacies with a prescription. For the global cannabis audience — including the OZH Times community — this isn’t just a legal update, but an opening to innovation, wellness and industry growth. In this article, we explore the details of the decree, its impact on patients, producers and cannabis-technology, and the challenges ahead.
Regulatory context and key updates
Since the 2016 law regulating medicinal and scientific use of cannabis (Law 1787), Colombia had allowed derivatives but maintained restrictions on domestic retail sale of dried flower, favouring export.
Now, a decree recognizes cannabis flower as a “finished product” for human and veterinary use, allowing sales in pharmacies and drugstores with a doctor’s prescription. This opens a domestic market that was previously largely restricted or exported.
The new regulation also redefines the responsibilities of regulatory agencies, introduces specific licenses for cultivation, processing and commercialization, and aims to ease access for small and medium producers.
With this move, Colombia positions itself as a leading regional example in medicinal cannabis regulation.
Impact for patients and therapeutic access
For patients, this new regulation means more direct access to medicinal flower — previously reliant on longer supply chains, higher cost and limited formal availability. The ability to purchase flower in pharmacies with a medical prescription reduces barriers and may improve quality and safety of treatment.
The inclusion of the raw flower form expands available presentations, enabling greater personalization and better adaptation to clinical conditions (chronic pain, spasms, side effects of treatment, etc.).
However, access will depend on how well the regulated supply chain functions: traceability, licensing, product calibration and health-professional training will determine whether patients truly benefit.
Opportunities for the industry and cannabis innovation
The domestic sale of flower opens multiple fronts for innovation:
- Optimized cultivation technologies for medicinal flower (genetics, terpenes, cannabinoids).
- Digital traceability platforms to ensure quality and compliance.
- Consumption/delivery devices that enhance therapeutic experience (for example, herbal vaporizers that maximize terpene profiles and reduce contaminants).
- Business models for small/medium producers previously dedicated to export or informal markets.
In this sense, the Latin American cannabis community sees Colombia as an innovation lab: a regulation that opens the internal market may accelerate value creation and adoption of more conscious practices.
Challenges and critical factors to monitor
Despite progress, this new framework comes with challenges that must be carefully managed:
- Implementation: licenses, production processes, sanitary certification and distribution must be efficient so patients are not left behind by bureaucracy.
- Inclusion of small producers: it is essential that regulation does not favour only large players and leave out those already operating locally.
- Quality and safety: ensuring the commercial flower meets pharmaceutical-grade standards (pesticide-free, heavy metals absent, mould free) is crucial for therapy and sector reputation.
- Professional and user education: both physicians and patients must be informed about use, dosage, side effects and consumption methods (including safer options like vaporization).
- Parallel market risk: until the legal supply becomes agile, the informal market may persist, with lower quality and greater risk to patients.
Colombia has opened a decisive door for medicinal cannabis in its most natural form: the flower. This moment could mark a turning point toward a consumption model that is more conscious, controlled and technologically supported.
For the global cannabis community, this represents an opportunity to observe how innovation (cultivation, traceability, consumption) integrates with public health and economic development.
Looking ahead, the ideal scenario is where patients have safe access, the local industry grows with inclusion and quality, and consumption methods evolve toward cleaner and more efficient solutions: vaporisers, precise dosing, optimized genetics.
Are we witnessing the beginning of a new era where medicinal cannabis is responsibly integrated into health systems and lifestyles? For many, the answer is yes — and Colombia is now one of its epicentres.
We invite healthcare professionals, producers, innovators and users to stay informed and engage actively in this new regulatory phase of cannabis in Colombia. Let us build a community that understands, respects and promotes cannábic wellness.
English 
Spanish